Key result
Circulating IGF-1 levels were significantly higher in patients with obstructive hypertrophic cardiomyopathy compared to healthy controls, but were significantly lower in patients with a history of congestive heart failure.
Why the study?
Are circulating levels of IGF-1 and IGFBPs associated with the disease condition and occurrence of congestive heart failure in patients with hypertrophic cardiomyopathy?
Observational (n=139)
Are circulating levels of IGF-1 and IGFBPs associated with the disease condition and occurrence of congestive heart failure in patients with hypertrophic cardiomyopathy?
Absolute Event Rate: 285.7% vs 172.9%
p-value: p=<0.0001
Circulating levels of IGF-1 and IGFBP-1 correlate with the extent of myocardial injury and the progression to congestive heart failure in patients with hypertrophic cardiomyopathy.
Insulin-like growth factor-1 (IGF-1) is important in the hypertrophic response of the myocardium, so the present study was designed to elucidate whether the circulating levels of IGF-1 and its binding proteins (IGFBPs) are related to the disease condition of patients with hypertrophic cardiomyopathy (HCM), in particular the occurrence of congestive heart failure (CHF). The study group comprised 124 patients with HCM and 15 healthy control subjects. The HCM patients were subdivided into 3 groups: 39 with hypertrophic obstructive cardiomyopathy (HOCM), 67 with hypertrophic non-obstructive cardiomyopathy (HNCM), and 18 with HCM and a history of CHF (HF-HCM, n=18). Serum levels of IGF-1 and IGFBPs (IGFBP-1 and -3) were compared between groups. IGF-1 levels were significantly higher in patients with HOCM and HNCM, and lower in patients with HF-HCM than in control subjects (p<0.0001, p<0.005, and p<0.05, respectively). IGFBP-1 levels were significantly higher in patients with HF-HCM than in the other 3 groups (p<0.0001 for all). The findings suggest that circulating levels of IGF-1 and IGFBP-1 are related to the extent of myocardial injury in patients with HCM.
No takes yet. Share an insight, caveat, or question.
Saeki et al. (2002) conducted an observational in Hypertrophic Cardiomyopathy (n=139). Hypertrophic cardiomyopathy vs. Healthy controls was evaluated on Serum concentration of IGF-1 (ng/ml) in patients with hypertrophic obstructive cardiomyopathy (HOCM) vs controls (p=<0.0001). Circulating IGF-1 levels were significantly higher in patients with obstructive hypertrophic cardiomyopathy compared to healthy controls, but were significantly lower in patients with a history of congestive heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: